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Abstract
Type I interferons (IFN) are cytokines that are rapidly secreted upon microbial infections and regulate all aspects of the
immune response. In humans 15 type I IFN subtypes exist, of which IFN a2 and IFN b are used in the clinic for treatment of
different pathologies. IFN a2 and IFN b are non redundant in their expression and in their potency to exert specific
bioactivities. The more recently identified type III IFNs (3 IFN l or IL-28/IL-29) bind an unrelated cell-type restricted receptor.
Downstream of these two receptor complexes is a shared Jak/Stat pathway. Several mechanisms that contribute to the shut
down of the IFN-induced signaling have been described at the molecular level. In particular, it has long been known that
type I IFN induces the establishment of a desensitized state. In this work we asked how the IFN-induced desensitization
integrates into the network built by the multiple type I IFN subtypes and type III IFNs. We show that priming of cells with
either type I IFN or type III IFN interferes with the cell’s ability to further respond to all IFN a subtypes. Importantly, primed
cells are differentially desensitized in that they retain sensitivity to IFN b. We show that USP18 is necessary and sufficient to
induce differential desensitization, by impairing the formation of functional binding sites for IFN a2. Our data highlight a
new type of differential between IFNs a and IFN b and underline a cross-talk between type I and type III IFN. This cross-talk
could shed light on the reported genetic variation in the IFN l loci, which has been associated with persistence of hepatitis
C virus and patient’s response to IFN a2 therapy.
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Introduction
Type I and type III (IL-28/29) IFNs form two multigenic
families of pathogen-induced cytokines that exhibit common
bioactivities through binding to unrelated cell surface receptors
[1]. The numerous type I IFN subtypes (a/b/v) bind to a receptor
made of the ubiquitously expressed IFNAR1 and IFNAR2 chains.
Conversely, the type III IFNs (l1, 2, 3) bind to a receptor made of
the broadly expressed IL-10R2 and of IFNLR1 (IL-28Ra) whose
expression is cell type specific. Therefore, the response to type III
IFNs is tissue specific and appears to be mainly restricted to
epithelial cells [2].
Downstream of these two receptor complexes is a shared Jak/
Stat pathway, involving the Janus kinases Jak1 and Tyk2 that
phosphorylate Stat1, Stat2 and Stat3. Activated Stat1/2 associate
to IRF9 to yield the ISGF3 complex that induces transcription of
IFN-stimulated genes (ISG) [1]. Thus, in humans, the 18 subtypes
(13 a,1b,1v and 3 l) of the type I and type III IFN systems
induce a same gene subset and exhibit antiviral and antiprolifer-
ative activities through two independent cell surface receptors. In
addition, the type I IFNs are recognized as mediators linking
innate and adaptive immunity via their effect on the differentiation
and maturation of dendritic cells and T cells, activities not shared
with type III IFNs [3].
Among the type I IFNs, the a/v subtypes on the one hand and
the b subtype on the other are not equivalent, as they are
differentially produced upon microbial infections and exhibit
distinct bioactivities. The biological potency of any given subtype
is determined by both receptor binding parameters and receptor
density on target cells [4,5]. Hence, compared to IFN a2, IFN b
binds the receptor with higher affinity, forms a longer-lived
complex and is more potent at inducing translational control
signals, inhibiting cell growth and osteoclastogenesis [6,7,8]
(Moraga et al., submitted). Importantly, IFN a2 is routinely used
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22200in the clinic as in chronic HCV infection and several forms of
cancer, whereas IFN b is approved for treatment of multiple
sclerosis, considered an autoimmune disease [1].
The pleiotropic activities of IFNs must be tightly down
regulated in time and space and several mechanisms have been
shown to co-exist in order to attenuate IFN-initiated Jak/Stat
signaling (reviewed in [9]). In an in vivo model, Sarasin et al showed
that liver cells from mice repeatedly injected with murine IFN a
become refractory to further IFN a stimulation [10]. The ISG-
encoded isopeptidase USP18/Ubp43 was found to be essential for
the establishment of the desensitized state [10,11]. USP18 can
remove the ubiquitin-like ISG15 from target proteins [12] and was
found to inhibit IFN-induced Jak/Stat signaling when constitu-
tively expressed in cultured cells [13]. Interestingly, USP18
expression was recently identified as a bad prognostic marker of
the success of IFN a therapy in patients with chronic hepatitis C
[14,15].
Here, we have studied how IFN induced desensitization
integrates into the network built by the multiple type I and type
III IFNs. We found that both type I and type III IFNs can induce a
long lasting desensitization state in cells of different lineages,
including human primary hepatocytes. Remarkably, the refractory
state is targeted to the IFN a and v subtypes, leaving nearly intact
the cells’ responsiveness to b and l IFNs. We show that USP18 is
necessary and sufficient to differentially desensitize cells by
disturbing the assembly of a IFNs with the receptor complex.
Altogether, our findings emphasize the existence of differential
activities within the type I IFN family and underline a novel type
I/III IFN cross-talk acting at the receptor level that could have
important consequences in the set up of clinical protocols,
especially for the treatment of HCV-infected patients who are
resistant to conventional pegylated IFN a2 therapy.
Results
Type I and type III IFNs induce desensitization to IFN a
In a first set of experiments, we established to what extent cells
that had responded to IFN a2, IFN b or IFN l1 could mount a
response to a second stimulation. For this, we used HLLR1-1.4
cells, a clone derived from human fibrosarcoma HT-1080 cells
stably expressing the IFNLR1 receptor chain and the luciferase
reporter gene controlled by an ISGF3-dependent promoter [16].
Thus, HLLR1-1.4 cells are responsive to type I IFNs as well as to
type III IFNs (Fig. 1B).
HLLR1-1.4 cells were left untreated (naı ¨ve) or stimulated
(primed) with IFN a2, IFN b or IFN l1 for 24 hr, thoroughly
washed and kept in fresh medium for another 24 hr (scheme in
Fig. 1A). Following this resting period, the levels of Jak/Stat
phosphorylation, luciferase activity and 29–59 oligo-adenylate-synthe-
tase (OAS 69K) mRNA in primed cells had nearly returned to basal
levels. Naı ¨ve and primed HLLR1-1.4 cells were challenged with
IFN a2, IFN b or IFN l1 for 6 hr (Fig. 1A) and luciferase activity
was quantified (Fig. 1B). The potency of IFN a2 in luciferase
induction (expressed as EC50) decreased 14.5–68.9 fold in primed
cells as compared to naı ¨ve cells, whereas the potency of IFN b
decreased only 2.1–3.2 fold (Fig. 1B). A similar trend was observed
when naı ¨ve and primed cells were monitored by RT-qPCR for
induction of OAS 69K mRNA in response to 10 pM of each IFN
(Fig. 1C). As shown in Fig. 1D, upon desensitization the dose
response relationship for IFN a2 had shifted down by a factor of
50-100. Interestingly, the activity of all the a/v subtypes assayed
was decreased in type I and in type III IFN-primed.
Desensitization was also evident at the level of early signaling
events. Fig. 2A shows that cells primed with IFN b or with IFN l1
were refractory to low doses (10 and 100 pM) of IFN a2 in terms
of tyrosine phosphorylation of Stat1, Stat2 and Stat3 (compare
lanes 2–3 with lanes 9–10 or 16–17). Conversely, in primed cells
Stat1, Stat2 and Stat3 were still phosphorylated upon treatment
with IFN b and IFN l1. Moreover, in primed cells the activation
of Jak1 and Tyk2, the earliest effectors of the pathway, was
abrogated in the case of IFN a2, but still detectable in the case of
IFN b and IFN l1 (Fig. 2B).
To better characterize the differential desensitization state, we
asked if primed cells resumed their response to IFNa2 when
stimulated for longer than 30 min. Naı ¨ve and primed cells were
thus stimulated with IFN a2 and IFN b for up to 8 hr. As shown in
Fig. 2C, the desensitization of primed cells to IFN a2 persisted,
independently of treatment duration. To define for how long
primed cells remained in a refractory state, we extended the
interval between priming and restimulation (washing of 24, 48 and
72 hr). As shown in Fig. 2D, primed cells had regained IFN a2
sensitivity after 72 hr in the absence of cytokine. In conclusion, the
differential desensitized state of the cell persists even at 8 hr of
stimulation, but is reversible as seen when cells are kept in the
absence of cytokine for 3 days.
Priming with type I IFN induced a similar a2/b differential
desensitized state in cell lines, such as bronchial epithelial BEAS-
2B and uroepithelial Hs 789.T cells, and in foreskin fibroblasts and
T cell blasts (Fig. 3A and 3B). Human primary hepatocytes
respond to type I IFNs and more weakly to IFN l1 (Fig. 3C,
compare level of P-Stat2, lanes 1–8). After 24 hr of priming with
either IFN a2 or IFN l1, hepatocytes expressed higher Stat2
protein and detectable levels of USP18, both proteins being
encoded by ISG (Fig. 3C, lanes 9–24). Importantly, primed
hepatocytes were desensitized to IFN a2 and only marginally to
IFN b (Fig. 3C, compare P-Stat2 in lanes 3, 11 and 19) and the
extent of desensitization was related to the level of sensitivity to the
priming cytokine. Of note, the basal phosphorylation level of Stat3
was reduced in IFN l1-primed cells with respect to naı ¨ve or IFN
a2-primed cells (compare P-Stat3 in lanes 1, 9 and 17). Overall,
these results demonstrate a previously unrecognized inhibitory
cross-talk between the type I and type III IFN systems.
Desensitized cells are impaired in their ability to bind IFN
a2
As shown above, cell desensitization to IFN a2 is manifest at the
level of Janus kinase activation and thus may result from reduced
surface level of the receptor chains or impaired binding of IFN a2.
FACS analysis clearly showed that naı ¨ve and primed (i.e.
desensitized) cells expressed equivalent levels of IFNAR1 and
IFNAR2 (Fig. 4A). Therefore, we tested whether the ligand
binding property of the receptor differed between naı ¨ve and
primed cells. For this, we iodinated IFN a2 and, in place of IFN b
which cannot be iodinated without loss of bioactivity, we made use
of an engineered mutant of IFN a2 (IFN a2-HEQ) whose affinity
for IFNAR1 is similar to that of IFN b and which recapitulates
IFN b unique biological activities [6]. Accordingly, in primed
HLLR1-1.4 cells, IFN a2-HEQ was as potent as IFN b in
inducing Stat phosphorylation (Fig. 4B). On this basis, we
compared the binding of
125I-IFN a2 and
125I-IFN a2-HEQ to
naı ¨ve and to primed HLLR1-1.4 cells. Fig. 4C shows that the
binding of
125I-IFN a2 was reduced in both IFN b-primed cells
and IFN l1-primed cells with respect to naı ¨ve cells. The reduction
was most apparent for low
125I-IFN a2 concentrations, matching
the decrease in specific biological activity (Fig. 1D). In contrast, the
binding of
125I-IFN a2-HEQ was only marginally reduced in
primed cells with respect to naı ¨ve cells (Fig. 4D). In conclusion,
despite unaltered levels of IFNAR1 and IFNAR2, cells primed
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assemble a functional IFN a2 receptor complex.
Expression of USP18 is necessary and sufficient to cause
differential desensitization
USP18 has been shown to downmodulate type I IFN activity
through binding to IFNAR2 [13], and we therefore tested its role in
differential desensitization. In HLLR1-1.4 cells USP18 mRNA was
induced by a2, band l1 IFNs,but not by othercytokinessuch as IFN c
o rI L - 6( F i g .5 C ) .A c c o r d i n g l y ,c e l lp r i m i n gw i t hI F Nc or IL-6 did not
induce USP18 nor lead to a desensitized state (Fig. 5A and 5B). USP18
protein accumulated with similar kinetics in cells treated with IFN b or
IFN l1, reaching maximum level between 8 and 16 hr of stimulation
(Fig. 5D). As found in primary hepa t o c y t e s( F i g .3 C ) ,t w oU S P 1 8 -
specific bands of comparable intensity were consistently detected.
To study the involvement of USP18, its expression was silenced
in HLLR1-1.4 cells (Fig. 5E). Remarkably, cells wherein USP18
was efficiently silenced were not desensitized to IFN a2. Of note,
the level of Stat1/2 phosphorylation was higher in USP18-
silenced/primed cells (lanes 14, 15 and 17, 18) than in USP18-
silenced/naive cells (lanes 11, 12) and most likely this is
consequence of the higher content of these Stats in primed cells.
To determine if USP18 was sufficient to establish differential
desensitization, HLLR1-1.4 cells were stably transfected with a
Figure 1. Differential desensitization studies in HLLR1-1.4 cells. (A) Protocol used to measure desensitization. Unless otherwise indicated,
cells were primed with IFN a2 or IFN b (500 pM) or IFN l1 (50 pM). The priming phase varied between 8 and 24 hr and the resting phase between 16
and 24 hr. Cells were then challenged with IFN for different times depending of the read out. (B) Graphic representation of the EC50 (pM) as
determined by the luciferase activity induced by IFN a2, IFN b or IFN l1 in naı ¨ve or primed cells. EC50 were calculated from the non-linear regression
fits of the luciferase activity induced by IFN in a concentration range covering 2.4 log. Priming and resting times lasted 24 hr each. Bars represent the
95% confidence limits. (C) Level of OAS-69K mRNA induced by IFN a2 (10 pM), IFN b (10 pM) or IFN l1 (50 pM) in naı ¨ve and primed cells as
determined by RT-qPCR. Data are expressed as ratios to GAPDH levels. Priming and resting times lasted 24 hr each. Bars represent the 95%
confidence limits (Student’s t-test). (D) Dose response induction profile of OAS-69K mRNA in naı ¨ve (closed symbols) and IFN a2 primed cells (open
symbols) stimulated for 4 hr with different doses of IFN a2 (circles) or IFN b (squares) as determined by RT-qPCR. Priming and resting times lasted 24
hr each. Data are expressed as ratios to GAPDH levels. Bars represent the 95% confidence limits (Student’s t-test).
doi:10.1371/journal.pone.0022200.g001
Differential Desensitization to Type I Interferons
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22200USP18 expression vector or an empty vector. In the 10 positive
clones analysed, the level of ectopic USP18 was higher (4 to 50
fold) than endogenous USP18 present in 8 hr-primed cells. Clone
HU13 was chosen as it expressed the least USP18 (Fig. 6A). We
checked the integrity of the deISGylase activity of USP18
expressed in clone HU13 by comparing the steady state level of
ISGylated conjugates in IFN b-treated parental and HU13 cells
(data not shown). The response to IFN a2, IFN b and IFN l1 was
measured. Compared to naı ¨ve HLLR1-1.4 cells, clone HU13 was
severely impaired in its phosphorylation response to IFN a2.
Conversely, responses to IFN b and IFN l1 were preserved or
slightly reduced (Fig. 6A–C). By directly comparing luciferase
induction in a control clone (HP1) and in HU13 clone, it appeared
that constitutive USP18 in HU13 shifted the dose response
relationship so that higher concentration of IFN a2 was required
to trigger a response of the same magnitude (Fig. 6D). All IFN a
subtypes tested and IFN v were found to be between 25 to 85-fold
less potent on HU13 cells than on control HP1 cells, whereas the
activities of IFN b and IFN l1 were marginally reduced (Fig. 6E).
The specific activity of IFN a2-HEQ, engineered for higher
binding towards IFNAR1 (see above), was reduced only by a factor
of 10 on HU13 cells (Fig. 6E), in accordance with the level of
activity of this mutant on cells desensitized by IFN priming
(Fig. 4B). On the other hand, the specific activity of IFN a2-a8tail,
an IFN a2 mutant engineered for higher IFNAR2 binding [7], was
decreased by a factor of 45 on HU13 cells as compared to HP1
cells (Fig. 6E). These results indicate that the affinity of a given IFN
a subtype towards IFNAR1 determines the degree of USP18-
dependent desensitization to that subtype.
As shown for desensitization caused by IFN priming (Fig. 4A),
desensitization caused by expression of USP18 was not dependent
on a change of IFNAR1 or IFNAR2 cell surface expression
(Fig. 7A). In studies analogous to those performed on IFN-primed
cells, we measured binding of radiolabeled ligands on HU13 and
Figure 2. Differential desensitization studies in HLLR1-1.4 cells. (A) Level of phosphorylation of Stat1, Stat2 and Stat3 induced at 30 min by
the indicated doses of IFN in naı ¨ve cells and in primed cells. Priming was for 8 hr and resting was for 16 hr. Cell lysates (30 mg) were fractionated on a
7% SDS polyacrylamide gel and immunoblotted with the indicated Abs. (B) Level of tyrosine phosphorylation of immunoprecipitated Tyk2 and Jak1
induced at 30 min by IFN a2 (100 pM), IFN b (100 pM) or IFN l1 (50 pM) in naı ¨ve and primed cells. Priming was for 8 hr and resting was for 16 hr.
Lysates (2 mg) were immunoprecipitated with Tyk2 Abs (top) or Jak1 Abs (bottom). The top membrane was incubated with phospho-tyrosine 4G10
mAb (P-Tyr) and the bottom membrane with phospho-Jak1 Abs. Protein content was assessed by re-blotting with Tyk2 or Jak1 specific Abs. (C)
Kinetics of Stat1, Stat2 and Stat3 phosphorylation in naı ¨ve and primed cells. Cells were stimulated with 50 pM of IFN a2 or IFN b, as indicated. Priming
was for 8 hr and resting was for 16 hr. Lysates (30 mg) were fractionated on a 7% SDS polyacrylamide gel and immunoblotted with the indicated Abs.
(D) Level of phosphorylation of Stat2 induced at 30 min by 100 pM of IFN in naı ¨ve cells and in primed cells. Priming was for 8 hr and the resting phase
varied from 24 hr to 72 hr. Cell lysates (30 mg) were fractionated on a 7% SDS polyacrylamide gel and immunoblotted with the indicated Abs.
doi:10.1371/journal.pone.0022200.g002
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22200Figure 3. Differential desensitization of human primary cells. (A) Human foreskin fibroblasts and (B) human T cells were either left untreated
(naı ¨ve) or primed for 8 hr. Cells were washed, maintained in medium without IFN for 16 hr and stimulated for 30 min with 10 and 100 pM of the
indicated IFN. Cell lysates (30 mg) were analysed with the indicated Abs. (C) Human primary hepatocytes were left untreated (naı ¨ve) or primed with
500 pM of IFN a2 or 30 nM of IFN l1 for 24 hr. Cells were washed, maintained in medium without IFN for 24 hr and stimulated for 30 min with the
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125I-IFN a2 on HU13 cells was
clearly reduced (Fig. 7B) and this to the same extent as for IFN-
primed HLLR1-1.4 cells (see Fig. 4C). As expected, the binding of
125I-IFN a2-HEQ was similar for the two clones (Fig. 7C). In
conclusion, these data demonstrate that the sole expression of
USP18 recapitulates the binding alteration observed in IFN-
primed (i.e. desensitized) cells.
Discussion
The major findings of our study are hereafter summarized: i)
type I IFN and type III IFN desensitize cells to several a IFNs but
only marginally to IFN b; ii) cells of different lineages - including
primary hepatocytes - undergo differential desensitization; iii) the
extent of desensitization is controlled by the level of an ISG,
USP18; vi) forced expression of USP18 in naive cells blunts IFN a
response at the level of its assembly to the receptor complex.
USP18 is a cysteine protease specialized in the removal of
ISG15 from ISGylated proteins. However, the phenotypic
alterations caused by USP18 deletion in the mouse have been
dissociated from ISG15-dependent mechanisms [17,18,19]. One
group has proposed that USP18 attenuates IFN a signaling
regardless of the isopeptidase activity of the protein by compet-
itively displacing Jak1 from its interaction with IFNAR2 [13]. We
Figure 4. Analysis of the type I IFN receptor in naı ¨ve and primed HLLR1-1.4 cells. (A) Surface level of IFNAR1 and IFNAR2 in naı ¨ve cells and
in IFN b or IFN l1-primed cells as determined by FACS. Cells were primed for 24 hr, washed and maintained in medium without IFN for 24 hr. Cells
were then stained with AA3 mAb (IFNAR1) or CD118 mAb (IFNAR2) followed by biotinylated rat anti-mouse Ab and streptavidin-PE. (B) Level of
phosphorylation of Stat1 in naı ¨ve and primed cells stimulated for 30 min with 100 pM of IFN a2, IFN b or IFN a2-HEQ. Lysates (30 mg) were
immunoblotted with the indicated antibodies. Priming was for 8 hr followed by 16 hr resting in medium without IFN. (C and D) Binding of
125I
labelled IFN a2 (C) or IFN a2-HEQ (D) at 37uC for 1 hr to naı ¨ve (closed circles), IFN b-primed cells (triangles) or IFN l1-primed cells (open circles). Cells
were primed for 8 hr and maintained without IFN for 16 hr.
doi:10.1371/journal.pone.0022200.g004
indicated IFN doses. Cell lysates (50 mg) were analysed with the indicated Abs to evaluate tyrosine phosphorylation and content of Jak1 and Stats.
The arrow points to the band corresponding to phosphorylated Jak1. The level of USP18 (bottom panel) was assessed in a 10% SDS PAGE. Of the two
USP18 bands (apparent MW of 38 and 35 kDa), the faster migrating one results from proteolytic processing [46]. This latter comigrates with a non
specific cross-reacting band detected in naı ¨ve cells and indicated by the asterisk (bottom panel).
doi:10.1371/journal.pone.0022200.g003
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22200Figure 5. USP18 is necessary for differential desensitization. (A) Stat1 phosphorylation induced in HLLR1-1.4 cells stimulated for 30 min with
IFN a2 (100 pM), IFN b (100 pM) or IFN c (1 ng/ml) in naı ¨ve cells and in cells primed with either IFN b (500 pM) or IFN c (10 ng/ml). Cells were primed
for 8 hr and maintained without IFN for 16 hr. (B) Stat3 phosphorylation induced in HLLR1-1.4 stimulated for 30 min with with IFN a2 (100 pM), IFN b
(100 pM) or hIL-6 (10 ng/ml) in naı ¨ve cells and in cells primed with IFN b (500 pM) or hIL-6 (100 ng/ml). Cells were primed for 8 hr and maintained
without IFN for 16 hr. Lysates (30 mg) were immunoblotted with the indicated Abs. (C) Level of USP18 mRNA in HLLR1-1.4 cells stimulated for 6 hr
with IFN a2, IFN b (500 pM), IFN l1 (50 pM), IFN c (1 ng/ml) or hIL-6 (100 ng/ml) as determined by qRT-PCR. Each sample was run in triplicate.
Transcripts were normalized to the level of 18S transcripts. The ratios between treated and untreated samples in each subset are shown, taking as 1
the ratio in untreated samples. (D) Kinetic profile of USP18 induction in HLLR1-1.4 cells stimulated with 100 pM of IFN b or IFN l1 for the indicated
times. Cell lysates (30 mg) were immunoblotted with the indicated Abs. The asterisk points to a nonspecific band. (E) USP18 is necessary for
differential desensitization. HLLR1-1.4 cells were transfected with a control pool of siRNA (Control siRNA) or a pool of four USP18 targeting siRNA
(USP18 siRNA). Twenty four hr after transfection, cells were either left untreated (naı ¨ve) or primed for 8 hr with the indicated IFN. After 16 hr of
resting, cells were stimulated for 30 min with 100 pM of IFN a2 or IFN b. Cell lysates (30 mg) were analysed with the indicated antibodies. The asterisk
in the bottom panel points to a band cross-reacting with anti-USP18 Abs (see also USP18 blot in Fig. 3C). Individual USP18 targeting siRNA were also
used with similar results (data not shown).
doi:10.1371/journal.pone.0022200.g005
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22200Figure 6. USP18 is sufficient to induce differential desensitization. (A) Level of Stat2 and Stat1 phosphorylation induced by 30 min
stimulation with IFN a2 or IFN b in naı ¨ve and primed HLLR1-1.4 cells and in clone HU13 stably expressing USP18. Level of USP18 in naı ¨ve and primed
HLLR1-1.4 cells (endogenous USP18) and in HU13 cells (ectopic USP18). Level of ISG15, a typical ISG, in naı ¨ve and primed HLLR1-1.4 and in HU13 cells.
Loading was evaluated by measuring AKT. Lysates (30 mg) were immunoblotted with the indicated Abs. (B) Kinetics of Tyk2, Stat1 and Stat2
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inactive USP18 impairs IFN signaling when highly and stably
expressed in naı ¨ve cells. In this context, however, desensitization is
severe and not differential, as cells become refractory to IFN a and
b subtypes. At present, we cannot exclude the possibility that the
isopeptidase activity of USP18 could be required in certain
physiological contexts, for instance when USP18 is below a given
threshold or when the level of ISG15 conjugates is maximal. In
Figure 7. Cells expressing USP18 are defective in IFN a2 binding. (A) Cell surface levels of IFNAR1 (left) and IFNAR2 (right) in parental HLLR1-
1.4 cells, USP18-expressing clone HU13 and control clone HP1was determined by FACS. Binding of
125I labelled IFN a2 (B), or IFN a2-HEQ (C) at 37uC
for 1 hr on HLLR1-1.4 cells (closed circles) and clone HU13 (triangles).
doi:10.1371/journal.pone.0022200.g007
phosphorylation in the USP18-expressing clone HU13 and in the parental HLLR1-1.4 cells. Cells were stimulated as indicated with 100 pM of IFN a2o r
IFN b. Lysates (30 mg) were immunoblotted with the indicated Abs. (C) Kinetics of Tyk2 and Stat1/2 phosphorylation in parental HLLR1-1.4 cells and
USP18-expressing HU13 cells. Cells were stimulated as indicated with 30 pM of IFN l1. (D) Luciferase activity induced by IFN a2 (closed circles) or IFN
b (open circles) in HP1 control clone and in HU13 clone constitutively expressing USP18. (E) Ratio of the EC50 values determined for luciferase activity
on the control clone HP1 and clone HU13. Cells were stimulated with the indicated IFN subtypes for 6 hr. Bars represent support limits of the ratio
from 95% confidence intervals of the individual EC50.
doi:10.1371/journal.pone.0022200.g006
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constitutive USP18 expression in naı ¨ve cells, it is also conceivable
that the native protein acquires distinctive biochemical properties -
in terms of stability, partners and/or substrates - when it gradually
accumulates in IFN-stimulated cells, along with the ISGylation
manchinery. On that line, additional work is required to
understand the functional link between USP18, ISG15 and the
ISGylation machinery in desensitization. Interestingly, several
features of the ISG15 system are closely related to the ubiquitin
system [20]. Notably, ISG15 is the only ubiquitin-like molecule
whose C-terminal residues (LRLRGG) are identical to those of
ubiquitin. These similarities suggest functional or regulatory
overlap between the two pathways and indeed, in vitro, murine
USP18 can remove ubiquitin from substrates [21,22].
From in vitro studies, it is known that the assembly of the IFN a2-
receptor complex on artificial membranes is conditioned by the
IFNAR1 concentration, whereas IFN b recruits IFNAR1 even if
present at very low concentration [6]. Indeed, in cells the surface
level of IFNAR1 is critical for the intensity of IFN a signaling
[5,23,24]. Importantly and in accordance with other reports
[13,25], we found that the presence of USP18 has no effect on the
global cell surface level of IFNAR2 and IFNAR1. Nonetheless, our
study shows that binding of IFN a is impaired in cells expressing
USP18, whether IFN-primed or USP18-transfected. Overall, we
favor a model whereby the interaction of USP18 with IFNAR2
([13] and our data) may lead to a re-organization of the
architecture of the type I IFN receptor. A change in lateral
mobility of the receptor chains, in their localisation in membrane
microdomains or their physical preassociation could weaken
assembling and signaling of IFN a2. Conversely, owing to its
higher affinity for the receptor, IFN b would retain activity on
USP18-expressing cells.
It is remarkable that, at least in humans, the 13 a IFNs exhibit
non-optimal affinity to the receptor chains and it is precisely this
weakness that allows a/b differential bioactivities and desensitiza-
tion [6]. Thus, in a viral infection, abundant IFN a is likely to be
inducedfrom themultiplegenesandlimitsthespread ofthevirusby
exerting potent antiviral action in a timely regulated mode on cells
that will then be desensitized. On the other hand, the single IFN b -
that is induced alone or, in response to viral infection, co-induced
with IFN a [26] - is optimized to bind the receptor chains with high
affinity and retains activity on cells desensitized for IFN a.T h i s
exclusive property of IFN b may be critical for the stimulation of
adaptive immune responses necessary to eradicate the virus.
Type I IFNs and type III IFNs are induced by similar stimuli,
exhibit common bioactivities and synergyze in antiviral activity
towards several viruses, including HCV [27,28,29]. Their
functional overlap was somehow expected given the activation,
through different receptors, of the same transcriptional factor
ISGF3 [30]. This is the first report of an inhibitory effect exerted
by IFN l upon IFN a activities. One particular context where
cellular desensitization to IFN a could be relevant is the
therapeutical control of chronic HCV infection. The current
standard therapy is pegylated-IFN a2 and ribavirin, whose success
is influenced by the virus genotype and multiple host factors.
Among the strongest predictive factors of treatment outcome is the
expression level of ISGs in liver tissue. Indeed, high baseline ISG
expression in hepatocytes has been consistently associated with
poor response to therapy [14,15,31,32,33]. Intrahepatic differenc-
es in ISG expression may reflect differences in host innate antiviral
responses before and/or during the chronic phase. The ISG
«signature» is likely to be driven and maintained by local innate
cytokines, such as IFNs, and may ultimately result in failure to
respond to therapeutic IFN.
Interestingly, USP18 is a component of the gene signature
predictive of poor treatment response [15,32,33]. Moreover, the
knockdown of USP18 in hepatoma cells was shown to potentiate
the anti-HCV effect of IFN a [11]. Here, we provide evidence that
primary human hepatocytes respond to IFN l and, when primed
with it, they express USP18 and become desensitized to IFN a2.
Thus, it is tempting to speculate that this USP18-mediated
refractoriness to IFN a could contribute, at least in part, to lower
the effectiveness of an IFN a-based therapy. In that event, IFN b
or l would represent alternative therapeutic approaches.
Another strong predictive factor of successful treatment of
chronically HCV infected patients (and spontaneous viral
clearance) is the IFN l3 (IL28B) genotype. Paradoxically, the
good response IFN l variant, ie predicting higher success rate of
IFN a-based therapy, was found to be associated with higher viral
load [34,35,36,37]. These consistent observations have spurred
intensive studies to try to relate the IFN l3 (IL28B) genotype with
the level of hepatic ISG[33,38,39,40]. To date contradictory
conclusions have been reported that do not yet provide a clear
picture. Likewise, we are still missing consistent analyses of which
of the variants, if any, alters expression level and/or potency of
IFN l.
In view of these and our present data, one can speculate that a
patient with the hapless genotype may induce IFN l inappropri-
ately (e.g. altered level, potency or timing) upon HCV infection.
On the one hand, this will lower the viral load without however
clearing the virus and, on the other hand, will maintain a high
level of ISGs, including USP18. Sustained level of USP18 may
contribute, at least in part, to desensitize liver cells to administered
IFN a.
Materials and Methods
Cells
HLLR1-1.4 cells are described in [16]. HLLR1-1.4 and derived
clones were cultured in DMEM with 10% fetal calf serum (FCS),
hypoxanthine, thymidine and aminopterin (HAT) and 400 mg/ml
G418. To obtain HU and HUS clones, HLLR1-1.4 cells were co-
transfected with pSVpuro and pMet7 empty vector or pMet7
encoding USP18 using FuGENE6 (Roche Applied Science).
Colonies selected in 0.4 mg/ml puromycin were analysed by
immunoblot for USP18 level as compared to primed HLLR1-1.4
cells. Primary hepatocytes were isolated as described [41] from a
human liver sample obtained from a 51 y-o female with
intrahepatic lithiasis. The French National Ethics Committee
has authorized the use of these samples for research. The patient
was free of any HCV, HBV and HIV markers at the time of
surgery. Hepatocytes were plated at confluence in a 12-well plates
at 10
6 cell/well precoated with collagen in culture medium
consisting of Williams’ E and Ham’s F-12 (Sigma) (1/1 in volume).
For the first 24 h, 5% FCS (Gibco) was added to favor cell
attachment. The standard medium was then replaced with 1 ml of
serum-free medium as described [41]. Cultures were incubated at
37uC and 5% CO2.
Plasmids and reagents
USP18 cDNA was cloned by PCR using as template the cDNA
prepared from HLLR1-1.4 cells stimulated with IFN b-treated for
6 hr and as primers: forward 59TTTGATATCCTGGGGGTT-
TTGGAGTGA39 and reverse 59TAGACCGGTCTGAAGG-
TTTTGGGCATTTC 39. The PCR product was subcloned in
pMET7 vector. The catalytic activity of USP18 was assessed by
comparing the global protein ISGylation level in 293T cells
transiently transfected with ISG15, E1, E2 and E3 enzymes of the
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IFN a2b was a gift of D. Gewert (Wellcome, UK) and IFN b was
from Biogen Idec (Boston, MA). Mutants IFN a2-HEQ and IFN
a2-a8tail were described in [6,42]. IFN a1, a8 and a21 were
produced as in [43]. IFN v was from G.R. Adolf (Bender, Wien).
All IFNs were purified to homogeneity. Hyper-IL-6, chimeric
fusion of human IL-6 and IL-6Ra, was a gift of Merck Serono S.A.
Human IFN c was from PBL, Biochemical Laboratories and IFN
l1 from Peprotech.
Luciferase reporter assay
To measure luciferase activity, cells were plated in 96-well plate
and treated in triplicate for 6 hr with 9 dilutions of IFN in a
concentration range covering 2.4 log. Cells were lysed and
luciferase activity was quantified in a luminometer (LB960
Berthold). Non-linear regression fits and determination of EC50
were done using Prism 5 (GraphPad software).
Quantitative real-time PCR
Cells were treated with IFN for 4 hr. Total RNA was purified
with RNeasy columns (Qiagen). Reverse transcriptions were
primed with random primers and performed using Moloney
murine leukemia virus reverse transcriptase (Invitrogen). Quanti-
tative real-time PCR (qRT-PCR) was performed using the
TaqMan gene expression assay technology (Applied Biosystems)
for USP18 (catalog no. Hs00276441). Each sample was run in
triplicate, normalized to the 18S RNA amplification level in the
same sample, and calculated relative to the expression of the target
gene in unstimulated cells. For measuring OAS 69K mRNA, qRT-
PCR assays were performed as in [26]. Quantification data are
presented as the 95% confidence limits of ratio to the
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) level.
Protein analysis
Cells were processed as in [44]. Polyclonal antibodies (Abs) used
were: anti-phospho-Tyr1054/Tyr1055 Tyk2 (Calbiochem); anti-
phospho-Tyr689 Stat2; anti-phospho-Tyr701 Stat1, anti-phospho-
Tyr705 Stat3, and anti-USP18 (a gift from D.E. Zhang, The
Scripps Research Institute, La Jolla, CA), anti-Jak1 (UBI, Lake
Placid, NY), anti-Jak1-phospho-YY1022/23 (Biosource, CA) and
anti-pan Akt (Cell Signaling Technology, Beverly, MA). Mouse
mAbs were anti-Tyk2 T10-2 (Hybridolab, Institut Pasteur,
France); anti-phosphotyrosine 4G10 (UBI, Lake Placid, NY) and
anti-ISG15 clone 2.1 (a gift from E.C Borden, Cleveland Clinic,
Cleveland, Ohio). Signal was revealed with the ECL enhanced
chemiluminescence Western blotting reagent (Pierce) or the more
sensitive Western Lightning Chemiluminescence Reagent Plus
(PerkinElmer). Signals were acquired and quantified with a Kodak
Image Station 440 cf. For flow cytometric analyses we used mAbs
anti-IFNAR1 AA3 (BiogenIdec, Boston) and anti-IFNAR2 CD118
(P,BL, Piscataway, NJ) or D5 (BiogenIdec, Boston) as in [44].
Samples were analysed with Becton Dickinson FACScan or Canto
flow cytometers.
IFN binding assays
IFN a2 and IFN a2-HEQ (30 mg) were labelled with Iodine
125
(PerkinElmer, NEZ033A) by using a modified chloramine T
method [45]. The labelled IFN preparations were titrated using a
luciferase reporter assay relative to IFN a2 and IFN a2-HEQ
references of known molar concentrations. The actual incorpora-
tions and monomer concentrations were as follows: a2: 75 nM
and 54 Bq/fmol; a2-HEQ: 25 nM and 87 Bq/fmol.
For binding assays (Fig. 3C and D), naı ¨ve and 8 hr-primed
HLLR1-1.4 cells were seeded on 6-well plates (8610
5 cells/well)
and 16 hr later incubated for 1 hr at 37uC with different
concentrations of either
125I-IFN a2o r
125I-IFN a2-HEQ only
or in the presence of a 100 fold excess of unlabeled cold IFN a2-
HEQ competitor. Cells were washed three times in DMEM and
5% serum to eliminate unbound IFN, trypsinized, and counted for
125I using a c counter (Berthold). For binding assays on clones
(Fig. 6B and C), cells were seeded on 6-well plates (8610
5 cells/
well) and treated as above.
USP18 silencing
USP18 ON-TARGETplus SMARTpool and a control siRNA
(ON-TARGETplus non-targeting pool) were from Dharmacon.
Cells were transfected with 25 nM of siRNA using Lipofectamine
RNAi max reagent (Invitrogen), according to manufacturer’s
instructions. Twenty-four hr later, cells were either left untreated
or primed, washed and challenged with IFN a2 or IFN b for
30 min to measure activation of Stats (scheme in Fig. 1A).
The siRNAs constituting the USP18 ON-TARGETplus
SMARTpool were also tested individually.
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